Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Trials In China Rich But Challenging – Wyeth Exec

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Clinical trials in China have much potential and can be rewarding if pharmaceutical companies are willing to overcome challenges such as working with young researchers in China, who may not have much pharmaceutical experience, said Ling Su, Wyeth vice president of clinical research and development for Asia Pacific
Advertisement

Related Content

Focus On Clinical Trial Review Process In China Before Timeline Reform – Merck Exec
Focus On Clinical Trial Review Process In China Before Timeline Reform – Merck Exec
Advertisement
UsernamePublicRestriction

Register

SC068926

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel